Results 1 to 10 of about 6,298 (119)

Tirzepatide Attenuates Wire Injury-Induced Arterial Remodeling in Non-Diabetic and Diabetic Mice: Comparison with Semaglutide [PDF]

Biomedicines
Background: Glucose-dependent insulinotropic polypeptide receptor (GIPR) and glucagon-like peptide-1 receptor (GLP-1R) activation exert anti-diabetic and anti-obesity effects.
Yusaku Mori, Naoya Osaka, Michishige Terasaki, Hironori Yashima, Tomomi Saito, Daiki Tanno, Madoka Ogino, Makoto Ohara, Sho-Ichi Yamagishi   +8 more
doaj   +2 more sources

Real-world treatment satisfaction and experience with once-weekly tirzepatide: Insights from prescribing physicians and people with obesity or overweight [PDF]

Obesity Pillars
Background: Tirzepatide, a once-weekly glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist, has demonstrated its efficacy in clinical trials; however, real-world evidence on treatment satisfaction and ...
Theresa Hunter Gibble, Andrea Leith, Lewis Harrison, Claire Gerber, Sonya Kokil Raikar, Era Seth, Esther Artime   +6 more
doaj   +2 more sources

Impact of tirzepatide on systemic arterial stiffness assessed by cardio-ankle vascular index in individuals with obesity complicated by type 2 diabetes: A retrospective cohort study in Japan [PDF]

Obesity Pillars
Background: Tirzepatide, a multi-agonist incretin agent that targets body weight and metabolic parameters, has stronger weight reduction and glycemic control effects than existing agents.
Daiji Nagayama, Miwako Wakamatsu, Yasuhiro Watanabe, Maika Ikeda, Yuta Koshikawa, Osamu Horikawa, Sayaka Tsuji, Kohji Shirai, Atsuhito Saiki   +8 more
doaj   +2 more sources

Understanding reasons for initiation and experience with tirzepatide among individuals with obesity or overweight: Results from the PERCEPTIONS survey [PDF]

Obesity Pillars
Background: Obesity contributes to multiple complications, increased mortality, and reduced health-related quality of life (HRQoL). Tirzepatide demonstrated sustained weight reduction and improvements in HRQoL in the SURMOUNT studies.
Theresa Hunter Gibble, Harriet Makin, Claire Gerber, Catherine Bottomley, Xuanyao He, Sara Pisani, Michael Shepherd, Elizabeth Collins, Angela Golden, Harold Bays   +9 more
doaj   +2 more sources

Case Report: Rhabdomyolysis following initiation of tirzepatide

Frontiers in Pharmacology
We present the case of a 66-year-old woman who developed weakness, nausea, and vomiting accompanied by markedly elevated creatine kinase levels after first treatment with an increased dose of tirzepatide.
Micha Loebermann, CARLOS Fritzsche
exaly   +3 more sources

Tirzepatide and Cancer Risk in Individuals with and without Diabetes: A Systematic Review and Meta-Analysis [PDF]

Endocrinology and Metabolism
Background Data on the carcinogenic potential of tirzepatide from randomized controlled trials (RCTs) are limited. Furthermore, no meta-analysis has included all relevant RCTs to assess the cancer risk associated with tirzepatide.
A.B.M. Kamrul-Hasan, Muhammad Shah Alam, Deep Dutta, Thanikai Sasikanth, Fatema Tuz Zahura Aalpona, Lakshmi Nagendra   +5 more
doaj   +1 more source

Systolic blood pressure reduction with tirzepatide in patients with type 2 diabetes: insights from SURPASS clinical program

Cardiovascular Diabetology, 2023
Background Tirzepatide, a once-weekly glucose-dependent insulinotropic polypeptide/ glucagon-like peptide-1 receptor agonist, is approved in the United States, Europe and Japan for the treatment of type 2 diabetes.
Ildiko Lingvay, Ofri Mosenzon, Katelyn Brown, Xuewei Cui, Ciara O’Neill, Laura Fernández Landó, Hiren Patel   +6 more
doaj   +1 more source

Novel Dual Incretin Receptor Agonists in the Spectrum of Metabolic Diseases with a Focus on Tirzepatide: Real Game-Changers or Great Expectations? A Narrative Review

Biomedicines, 2023
The prevalence of metabolic diseases including type 2 diabetes (T2D), obesity and non-alcoholic fatty liver disease (NAFLD) increases globally. This highlights an unmet need for identifying optimal therapies for the management of these conditions ...
Alexandros Leonidas Liarakos, Chrysi Koliaki   +1 more
doaj   +1 more source

Tirzepatide for type 2 diabetes

Drugs in Context, 2023
One in ten adults worldwide is living with diabetes, with 95% having type 2 diabetes (T2D). Sustained glycaemic control in people with T2D is difficult to achieve despite recent advances in T2D management with the advent of glucagon-like peptide 1 ...
Sarah L Anderson, Joel C Marrs
doaj   +1 more source

Tirzepatide is an imbalanced and biased dual GIP and GLP-1 receptor agonist

JCI Insight, 2020
Tirzepatide (LY3298176) is a dual GIP and GLP-1 receptor agonist under development for the treatment of type 2 diabetes mellitus (T2DM), obesity, and nonalcoholic steatohepatitis.
Francis S. Willard, Jonathan D. Douros, Maria B.N. Gabe, Aaron D. Showalter, David B. Wainscott, Todd M. Suter, Megan E. Capozzi, Wijnand J.C. van der Velden, Cynthia Stutsman, Guemalli R. Cardona, Shweta Urva, Paul J. Emmerson, Jens J. Holst, David A. D’Alessio, Matthew P. Coghlan, Mette M. Rosenkilde, Jonathan E. Campbell, Kyle W. Sloop   +17 more
doaj   +1 more source